CTLA4 and nonpapillary renal cell carcinoma: A phase II clinical trial (NCT00057889) was conducted to evaluate the efficacy of ipilimumab (CTLA-4 inhibitor), which became the first immune checkpoint inhibitor (ICI) used to treat patients with metastatic ccRCC [111].